We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Telix Pharmaceuticals Limited is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $6.5 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $1.605 - $7.65 |
|---|---|
| 50-day moving average | $6.3728 |
| 200-day moving average | $5.0367 |
| Target price | $2.2 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.22 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$6.05
| 1 week (2021-09-17) | -18.90% |
|---|---|
| 1 month (2021-08-25) | -15.38% |
| 3 months (2021-06-25) | -5.02% |
| 6 months (2021-03-25) | 34.44% |
| 1 year (2020-09-25) | 256.93% |
|---|---|
| 2 years (2019-09-25) | 287.82% |
| 3 years (2018-09-25) | 646.91% |
| Revenue TTM | $6.5 million |
|---|---|
| Gross profit TTM | $3.2 million |
| Return on assets TTM | -33.94% |
| Return on equity TTM | -116.28% |
| Profit margin | 0% |
| Book value | 0.17 |
| Market capitalisation | $2.1 billion |
TTM: trailing 12 months
We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $1.605 up to $7.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.3847. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
We look at some of the biggest and best performing iron ore stocks in Australia.
Shares in the major banks have risen more than 50% in the last 12 months.
Steps to owning and managing China Evergrande Group shares from Australia.
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
Everything we know about the Lykos Metals IPO, plus information on how to buy in.
